

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 19, 2025

OCI-Ly3

RRID:CVCL_8800

Type: Cell Line

Proper Citation

(RRID:CVCL_8800)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8800

Proper Citation: (RRID:CVCL_8800)

Sex: Male

Defining Citation: [PMID:3567358](#), [PMID:8574164](#), [PMID:10676951](#), [PMID:11807979](#), [PMID:15122589](#), [PMID:18323416](#), [PMID:19278952](#), [PMID:20054396](#), [PMID:20628145](#), [PMID:20889926](#), [PMID:21179087](#), [PMID:22460905](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:23699601](#), [PMID:23321251](#), [PMID:25485619](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#)

Comments: Caution: A cell line, now termed GNE-587170 (Cellosaurus=CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: H3K9ac ChIP-seq epigenome analysis., Omics: Genome sequenced., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: OCI-Ly3

Synonyms: OCI-LY3, OCI-Iy3, OCI-LY-3, Oci-Ly-3, OCI-Ly 3, OCILY-3, OCI-Ly03, OCI Ly3, OCILY3, Ly3, LY3

Cross References: EFO:EFO_0006710, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:745, BioSample:SAMN10988130, cancercellines:CVCL_8800, Cell_Model_Passport:SIDM01778, ChEMBL-Cells:ChEMBL4523534, ChEMBL-Targets:ChEMBL4523565, Cosmic:1290019, Cosmic:1329094, Cosmic:1486584, Cosmic:1487544, Cosmic:1517647, Cosmic:1541901, Cosmic:1548654, Cosmic:1550337, Cosmic:1945198, Cosmic:2276329, Cosmic:2437309, DepMap:ACH-000158, DSMZ:ACC-761, DSMZCellDive:ACC-761, EGA:EGAS00001000610, ENCODE:ENCBS018GXW, ENCODE:ENCBS757GPD, GEO:GSM2023, GEO:GSM1963, GEO:GSM380133, GEO:GSM552451, GEO:GSM887472, GEO:GSM888552, GEO:GSM1035342, GEO:GSM1059799, GEO:GSM1374787, GEO:GSM1890025, GEO:GSM1890026, GEO:GSM1890027, GEO:GSM1890028, GEO:GSM3150251, IARC_TP53:26922, LiGeA:CCLE_060, Lonza:945, PharmacDB:OCILY3_1189_2019, PRIDE:PXD012087, Progenetix:CVCL_8800, PubChem_Cell_line:CVCL_8800, Wikidata:Q54931773

ID: CVCL_8800

Record Creation Time: 20250131T202146+0000

Record Last Update: 20250131T204000+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly3.

No alerts have been found for OCI-Ly3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. Cancer research

communications, 4(5), 1328.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. *The Journal of experimental medicine*, 221(5).

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Yang X, et al. (2023) Potential role of the P2X7 receptor in the proliferation of human diffused large B-cell lymphoma. *Purinergic signalling*.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. *International journal of cancer*, 148(1), 150.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. *Molecular cell*, 81(10), 2094.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Zhang J, et al. (2020) Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation. *Cell chemical biology*, 27(12), 1500.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. *Cell reports*, 31(13), 107840.

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. *Cell chemical biology*, 27(5), 538.

Gehring T, et al. (2019) MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells. *Cell reports*, 29(4), 873.

Reddy A, et al. (2017) Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. *Cell*, 171(2), 481.